OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Market Closed - Börse Stuttgart 04:03:12 2024-04-26 am EDT | ||
| 5.92 EUR | +1.20% |
|
| Current month | +31.56% | ||
| 1 month | +45.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.92 | +1.20% | 0 |
| 24-04-25 | 5.85 | +15.38% | 0 |
| 24-04-24 | 5.07 | +0.80% | 0 |
| 24-04-23 | 5.03 | +3.71% | 0 |
| 24-04-22 | 4.85 | +6.13% | 0 |
Delayed Quote Börse Stuttgart
Last update April 26, 2024 at 04:03 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD9LYZ |
| ISIN | DE000SD9LYZ9 |
| Date issued | 2020-12-15 |
| Strike | 6,935 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.52 € |
|---|---|
| Lowest since issue | 0.76 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
- Stock Market
- Certificates
- Certificat
